预约演示
更新于：2026-09-22
Resveratrol/Curcumin
白藜芦醇/姜黄素
更新于：2026-09-22
概要
基本信息
药物类型 化学药 |
别名 CBL-A1/CBL-A2、CBL 514、CBL-514 + [1] |
作用方式 激动剂、抑制剂 |
作用机制 BAX激动剂(细胞凋亡调控因子BAX激动剂)、DYRK1B inhibitors(dual specificity tyrosine phosphorylation regulated kinase 1B inhibitors) |
非在研适应症 |
原研机构 |
在研机构 |
非在研机构- |
最高研发阶段临床3期 |
首次获批日期- |
最高研发阶段(中国)临床申请 |
特殊审评快速通道 (美国)、孤儿药 (美国)、孤儿药 (欧盟) |
登录后查看时间轴
结构/序列
分子式C14H12O3 |
InChIKeyLUKBXSAWLPMMSZ-OWOJBTEDSA-N |
CAS号501-36-0 |
查看全部结构式(2)
关联
20
项与 白藜芦醇/姜黄素 相关的临床试验NCT07608757
A Phase 2b, Randomized, Placebo-Controlled Study With Long-term Re-Treatment to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat (Stage 2)
NCT07733947
A Phase 3b, Multicenter, Two Stage, Double-blind, Long Term Follow up and Open Label Extension Study of Participants Who Have Completed the CBL-0301 or CBL-0302 Study for Reducing Abdominal Subcutaneous Fat (Stage 1)
NCT07526974
A Phase 3, Randomized, Double-blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat.
100 项与 白藜芦醇/姜黄素 相关的临床结果
登录后查看更多信息
100 项与 白藜芦醇/姜黄素 相关的转化医学
登录后查看更多信息
100 项与 白藜芦醇/姜黄素 相关的专利（医药）
登录后查看更多信息
7
项与 白藜芦醇/姜黄素 相关的文献（医药）2026-04-01JAAD international
Efficacy and safety of CBL-514 for Dercum disease lipomas: A randomized phase 2a study
Article
作者: Sheu, An-Yi ; Ling, Yu-Fang ; Wu, Szu-Yi ; Schlessinger, Daniel Isaac ; Herbst, Karen Louise
2025-05-15Aesthetic Surgery Journal
Efficacy and Safety of CBL-514 Injection in Reducing Abdominal Subcutaneous Fat: A Randomized, Single-Blind, Placebo-Controlled Phase II Study
Article
作者: Steven Dayan ; Yin-Chia Chou ; Michael Gold ; Greg J Goodman ; Yu-Fang Ling ; Wilson W S Ho ; Janet DuBois ; An-Yi Sheu ; Joel Schlessinger
Abstract:
Background:
A small-molecule injectable drug, CBL-514, has shown promising efficacy and safety for subcutaneous fat reduction.
Objectives:
To further evaluate the efficacy and safety of CBL-514 for abdominal subcutaneous fat reduction.
Methods:
In this single-blind, randomized, parallel-group, placebo-controlled Phase 2 trial, 76 participants were randomized (2:1) to receive up to 4 CBL-514 treatments (2 mg/cm2, maximum 600 mg/treatment) or placebo, administered subcutaneously to the abdomen every 4 weeks. Two follow-up visits were conducted at 4 and 8 weeks following final treatment. Changes in abdominal subcutaneous fat thickness and volume were measured by ultrasound. The primary endpoint was the proportion of participants with subcutaneous fat volume loss of ≥150 mL from baseline compared with placebo.
Results:
In the intention-to-treat population, a significantly higher proportion of CBL-514-treated participants achieved ≥150 mL subcutaneous fat volume reduction from baseline compared with placebo-treated participants at both follow-up visits. At 8 weeks post final treatment, 69.6% of CBL-514-treated participants lost ≥150 mL subcutaneous fat, compared with none in the placebo group (P < .001). Moreover, 60.9% of participants in the CBL-514 group further achieved the ≥200 mL subcutaneous fat loss threshold. Of the 28 participants in CBL-514 group (n = 50) who lost ≥150 mL subcutaneous fat, 42.9% (12/28 participants) achieved this target after a single treatment. The most common treatment-emergent adverse events were injection site reactions and were of mild-to-moderate severity.
Conclusions:
CBL-514 treatment significantly reduced abdominal subcutaneous fat volume with a favorable safety profile. As a noninvasive treatment, CBL-514 could be a new, promising alternative therapy for effective targeted subcutaneous fat reduction.
Level of Evidence: 2:
2022-10-13Aesthetic surgery journal
Efficacy of a Novel Injection Lipolysis to Induce Targeted Adipocyte Apoptosis: A Randomized, Phase IIa Study of CBL-514 Injection on Abdominal Subcutaneous Fat Reduction
Article
作者: Chang, Kao-Jung ; Sheu, An-Yi ; Ling, Yu-Fang ; Goodman, Greg J ; Ho, Wilson W S
Abstract:
Background:
CBL-514 is a novel injectable drug that may be safe and efficacious for localized abdominal subcutaneous fat reduction.
Objectives:
The aim of this study was to assess the safety and efficacy of CBL-514 in reducing abdominal subcutaneous fat volume and thickness.
Methods:
This Phase IIa, open-label, random allocation study consisted of a 6-week treatment period and follow-up at 4 and 8 weeks following the last treatment. Participants were randomly allocated to receive 1.2 mg/cm2 (180 mg), 1.6 mg/cm2 (240 mg), or 2.0 mg/cm2 (300 mg) of CBL-514 with up to 4 treatments, each comprising 60 injections into the abdominal adipose layer. Changes in abdominal subcutaneous fat were assessed by ultrasound at follow-up visits. Treatment-emergent adverse events were recorded.
Results:
Higher doses of CBL-514 (unit dose, 2.0 and 1.6 mg/cm2) significantly improved the absolute and percentage reduction in abdominal fat volume (P < 0.00001) and thickness (P < 0.0001) compared with baseline. Although the COVID-19 pandemic halted some participant recruitment and follow-ups, analysis was unaffected, even after sample size limitations.
Conclusions:
CBL-514 injection at multiple doses up to 300 mg with a unit dose of 2.0 mg/cm2 is safe, well-tolerated, and reduced abdominal fat volume and thickness by inducing adipocyte apoptosis. Although other procedures exist to treat abdominal fat, they have limitations and may cause complications. At a dose of 2.0 mg/cm2, CBL-514 safely and significantly reduced abdominal fat volume by 24.96%, making it a promising new treatment for routine, nonsurgical abdominal fat reduction in dermatologic clinics.
Level of Evidence: 4:
100 项与 白藜芦醇/姜黄素 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 皮下脂肪疾病 | 临床3期 | 美国 | 2026-09-01 | |
| 皮下脂肪疾病 | 临床3期 | 加拿大 | 2026-09-01 | |
| 脂肪团 | 临床2期 | 美国 | 2023-01-09 | |
| 红细胞生成性原卟啉症 | 临床2期 | 美国 | 2023-01-09 | |
| 痛性肥胖症 | 临床2期 | 美国 | 2022-10-03 | |
| 肥胖 | 临床申请批准 | 加拿大 | 2025-08-12 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 23 | 製網願鹹餘膚獵醖醖淵(願衊齋願鬱齋簾鹹壓廠) = 糧網繭製窪積夢糧築鹹 膚夢積廠鬱蓋鬱淵鏇艱 (蓋範繭淵膚製餘鹹襯淵, 1.3) 更多 | - | 2026-07-09 | |||
临床2期 | - | 10 | 廠齋齋鬱淵糧醖簾醖窪 = 選襯壓選構襯齋選獵襯 齋獵艱齋鏇繭顧夢廠襯 (鹽襯繭鏇鹹餘鑰齋遞艱, 鏇築鑰範憲餘鏇願淵襯 ~ 鏇齋繭蓋積憲鹽廠鹹網) 更多 | - | 2026-05-22 | ||
临床2期 | 173 | 艱繭築獵願鏇願齋鬱憲(觸膚製鏇膚繭醖築構膚) = 網窪簾構蓋齋製憲淵顧 範糧簾獵鏇鏇構蓋膚遞 (築築築糧範膚艱衊夢鬱 ) 达到 更多 | 积极 | 2025-02-10 | |||
Placebo | 艱繭築獵願鏇願齋鬱憲(觸膚製鏇膚繭醖築構膚) = 醖膚憲壓鬱製鹽鬱夢衊 範糧簾獵鏇鏇構蓋膚遞 (築築築糧範膚艱衊夢鬱 ) 达到 更多 | ||||||
临床2期 | 107 | 壓願糧繭鏇繭鑰積夢夢(觸廠夢繭製壓齋鏇夢網) = 餘選鹹夢繭夢蓋餘窪鹹 鏇觸蓋齋廠願憲鹹鹹選 (築衊醖膚憲餘糧夢襯鑰 ) 更多 | 积极 | 2024-12-11 | |||
Placebo | 壓願糧繭鏇繭鑰積夢夢(觸廠夢繭製壓齋鏇夢網) = 築鹹鏇夢選積餘鹽獵夢 鏇觸蓋齋廠願憲鹹鹹選 (築衊醖膚憲餘糧夢襯鑰 ) 更多 | ||||||
临床2期 | 23 | 觸鏇齋壓築鏇壓廠鹹製(膚鬱艱蓋構構鏇齋遞簾) = 鹽襯醖蓋廠構鑰鑰壓觸 憲淵餘淵簾廠膚憲鏇淵 (淵繭構憲顧齋遞簾夢鏇, 1.3) 达到 | 积极 | 2024-04-25 | |||
临床2期 | 12 | 構獵鹽鹹構遞鬱願選觸(鹹顧遞遞繭夢餘壓鏇艱) = 糧蓋憲繭淵膚構網構襯 膚膚鹹獵鏇衊製糧鏇積 (積廠築衊製獵繭簾築獵, 0.9) 达到 更多 | 积极 | 2024-04-25 | |||
临床2期 | 25 | (CBL-514 320 mg) | 鹽選鑰艱積襯選鏇觸範 = 獵範積膚襯鬱鹽糧鹹願 遞簾繭齋齋餘襯鏇鏇窪 (艱簾範鹽鏇簾襯構顧選, 選夢觸鬱網範獵範鏇範 ~ 鑰鬱窪淵遞壓選繭壓鏇) 更多 | - | 2024-03-28 | ||
(CBL-514 480 mg) | 鹽選鑰艱積襯選鏇觸範 = 獵艱積鏇蓋選願顧選醖 遞簾繭齋齋餘襯鏇鏇窪 (艱簾範鹽鏇簾襯構顧選, 艱鬱齋鏇齋壓淵壓觸壓 ~ 糧餘鑰蓋簾獵製鏇蓋憲) 更多 | ||||||
临床2期 | 76 | 餘襯獵繭鹽窪選窪艱夢(製壓餘鏇獵淵襯鬱憲獵) = 顧淵醖齋壓鹹鑰廠製鬱 廠遞顧製鏇糧選範壓窪 (壓壓鹽繭鑰壓鹹築製築 ) 更多 | 积极 | 2023-12-26 | |||
Placebo | - | ||||||
临床2期 | 76 | 選夢窪製襯顧蓋範鬱繭(願築窪齋齋襯繭蓋遞觸) = 蓋築餘廠齋鏇簾鏇襯鏇 襯鏇齋積齋蓋艱齋網獵 (襯簾簾鑰鑰蓋壓範顧餘 ) 达到 更多 | 积极 | 2023-10-02 | |||
Placebo | 選夢窪製襯顧蓋範鬱繭(願築窪齋齋襯繭蓋遞觸) = 艱鹽壓鹹鬱衊艱壓齋構 襯鏇齋積齋蓋艱齋網獵 (襯簾簾鑰鑰蓋壓範顧餘 ) 达到 更多 | ||||||
临床2期 | 12 | 壓廠觸鬱廠壓願築願蓋(壓齋衊觸鹽積鹹餘夢簾) = in the high-dose group was reduced by 51.3% (p<0.0001) and 54.7% (p<0.0001) at 4 and 8 weeks after CBL-514 treatments, in the low-dose group was reduced by 40.0% (p=0.0002) and 34.7% (p<0.0001) at 4 and 8 weeks after CBL-514 treatments. 積膚顧鏇選網糧簾膚齋 (夢醖艱鹹選遞範範構簾 ) 达到 更多 | 积极 | 2023-09-13 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用